Literature DB >> 11148048

The skeletal muscle ryanodine receptor identified as a molecular target of [3H]azidodantrolene by photoaffinity labeling.

K Paul-Pletzer1, S S Palnitkar, L S Jimenez, H Morimoto, J Parness.   

Abstract

Dantrolene is a skeletal muscle relaxant which acts by inhibiting intracellular Ca(2+) release from sarcoplasmic reticulum (SR). It is used primarily in the treatment of malignant hyperthermia (MH), a pharmacogenetic sensitivity to volatile anesthetics resulting in massive intracellular Ca(2+) release. Determination of the site and mechanism of action of dantrolene should contribute to the understanding of the regulation of intracellular Ca(2+) release in skeletal muscle. Photoaffinity labeling of porcine SR with [(3)H]azidodantrolene, a photoactivatable analogue of dantrolene, has identified a 160 kDa SR protein with immunologic cross-reactivity to skeletal muscle ryanodine receptor (RyR) as a possible target [Palnitkar et al. (1999) J. Med. Chem. 42, 1872-1880]. Here we demonstrate specific, AMP-PCP-enhanced, [(3)H]azidodantrolene photolabeling of both the RyR monomer and a 160 or 172 kDa protein in porcine and rabbit SR, respectively. The 160/172 kDa protein is shown to be the NH(2)-terminus of the RyR cleaved from the monomer by an endogenous protease activity consistent with that of n-calpain. MALDI-mass spectrometric analysis of the porcine 160 kDa protein identifies it as the 1400 amino acid NH(2)-terminal fragment of the skeletal muscle RyR reportedly generated by n-calpain [Shevchenko et al. (1998) J. Membr. Biol. 161, 33-34]. Immunoprecipitation of solubilized, [(3)H]azidodantrolene-photolabeled SR protein reveals that the cleaved 160/172 kDa protein remains associated with the C-terminal, 410 kDa portion of the RyR. [(3)H]Dantrolene binding to both the intact and the n-calpain-cleaved channel RyR is similarly enhanced by AMP-PCP. n-Calpain cleavage of the RyR does not affect [(3)H]dantrolene binding in the presence of AMP-PCP, but depresses drug binding in the absence of nucleotide. These results demonstrate that the NH(2)-terminus of the RyR is a molecular target for dantrolene, and suggest a regulatory role for both n-calpain activity and ATP in the interaction of dantrolene with the RyR in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11148048     DOI: 10.1021/bi001502s

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  17 in total

1.  Mind the magnesium, in dantrolene suppression of malignant hyperthermia.

Authors:  Stephen C Cannon
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-25       Impact factor: 11.205

2.  Probing a putative dantrolene-binding site on the cardiac ryanodine receptor.

Authors:  Kalanethee Paul-Pletzer; Takeshi Yamamoto; Noriaki Ikemoto; Leslie S Jimenez; Hiromi Morimoto; Philip G Williams; Jianjie Ma; Jerome Parness
Journal:  Biochem J       Date:  2005-05-01       Impact factor: 3.857

3.  Ryanodine receptor type 1 (RyR1) possessing malignant hyperthermia mutation R615C exhibits heightened sensitivity to dysregulation by non-coplanar 2,2',3,5',6-pentachlorobiphenyl (PCB 95).

Authors:  Tram Anh Ta; Isaac N Pessah
Journal:  Neurotoxicology       Date:  2006-08-30       Impact factor: 4.294

4.  Acute changes in muscle blood flow and concomitant muscle damage after an intramuscular administration.

Authors:  Pierre Jean Ferré; Eckart Thein; Isabelle Raymond-Letron; Pierre-Louis Toutain; Hervé Pierre Lefebvre
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

5.  Essential Role of Calmodulin in RyR Inhibition by Dantrolene.

Authors:  Ye Win Oo; Nieves Gomez-Hurtado; Kafa Walweel; Dirk F van Helden; Mohammad S Imtiaz; Bjorn C Knollmann; Derek R Laver
Journal:  Mol Pharmacol       Date:  2015-04-28       Impact factor: 4.436

6.  Modulation of the oligomerization of isolated ryanodine receptors by their functional states.

Authors:  Xiao-Fang Hu; Xin Liang; Ke-Ying Chen; Hong Xie; Yuhong Xu; Pei-Hong Zhu; Jun Hu
Journal:  Biophys J       Date:  2005-06-10       Impact factor: 4.033

7.  Dynamic, inter-subunit interactions between the N-terminal and central mutation regions of cardiac ryanodine receptor.

Authors:  Zheng Liu; Ruiwu Wang; Xixi Tian; Xiaowei Zhong; Jaya Gangopadhyay; Richard Cole; Noriaki Ikemoto; S R Wayne Chen; Terence Wagenknecht
Journal:  J Cell Sci       Date:  2010-04-27       Impact factor: 5.285

8.  Localization of the dantrolene-binding sequence near the FK506-binding protein-binding site in the three-dimensional structure of the ryanodine receptor.

Authors:  Ruiwu Wang; Xiaowei Zhong; Xing Meng; Andrea Koop; Xixi Tian; Peter P Jones; Bradley R Fruen; Terence Wagenknecht; Zheng Liu; S R Wayne Chen
Journal:  J Biol Chem       Date:  2011-01-24       Impact factor: 5.157

9.  Dantrolene requires Mg2+ to arrest malignant hyperthermia.

Authors:  Rocky H Choi; Xaver Koenig; Bradley S Launikonis
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-03       Impact factor: 11.205

10.  Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene.

Authors:  Gennady Cherednichenko; Chris W Ward; Wei Feng; Elaine Cabrales; Luke Michaelson; Montserrat Samso; José R López; Paul D Allen; Isaac N Pessah
Journal:  Mol Pharmacol       Date:  2008-01-02       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.